...
首页> 外文期刊>Pituitary >An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies
【24h】

An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies

机译:成人患者患者患者患者患者患者的评价,包括与其他患者报告的结果措施的相关性:来自两个大型多中心国际研究的数据

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose The Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) is a new patient-reported outcome (PRO) measure for patients with acromegaly receiving injectable somatostatin analogs (SSAs) to assess clinical symptoms and adverse drug reaction interference, treatment satisfaction, and convenience. We evaluated its scale structure, reliability, validity, responsiveness, and what constitutes clinically meaningful change. Methods Data from two longitudinal studies (N = 79 and 82) of patients receiving a stable injectable SSA dose for >= 6 months who completed the Acro-TSQ and other collateral measures (e.g., AcroQoL, AIS, WPAI:SHP, EQ-5D-5L) were analyzed. Results The first study demonstrated internal consistency of the Acro-TSQ. However, several items had high ceiling effects, responsiveness could not be established, and the minimally important difference (MID) was not estimable. In the second study, factor analysis revealed six scales: Symptom Interference, Treatment Convenience, Injection Site Interference, GI Interference, Treatment Satisfaction, and Emotional Reaction. Internal consistency and test-retest reliability were confirmed; most scales demonstrated significant differences in mean scores by disease severity. Correlations between Acro-TSQ scales and other collateral measures exceeded 0.30 in absolute value, confirming convergent validity. Responsiveness in Acro-TSQ scale scores reflected improved disease control. The MID was estimated for Symptom Interference (10-12 points), Treatment Convenience (9-11) and GI Interference (8-10). Conclusions The Acro-TSQ is a brief, yet comprehensive tool to monitor important outcomes associated with injectable acromegaly SSA treatments. Its content reflects both disease and treatment burden as well as patient satisfaction, and its relevant for use in clinical studies.
机译:目的,ArmeMgaly治疗满意度问卷(ACRO-TSQ)是一种新的患者报告的结果(Pro)衡量患者,可用于接受可注射的生长抑素类似物(SSAS)评估临床症状和不良药物反应干扰,治疗满意度和便利性。我们评估其规模结构,可靠性,有效性,响应能力以及构成临床有意义的变化的内容。方法来自两个纵向研究(n = 79和82)的数据,患者接受稳定的可注射SSA剂量> = 6个月,用于完成ACRO-TSQ和其他抵押品措施(例如,Acroqol,AIS,WPAI:SHP,EQ-5D -5L)分析。结果第一项研究表明了ACRO-TSQ的内部一致性。然而,几个物品具有高天花板效应,无法建立响应性,并且最重要的重要差异(中间)不是估计的。在第二项研究中,因子分析显示六种尺度:症状干扰,治疗方便,注射部位干扰,GI干扰,治疗满意度和情绪反应。确认内部一致性和测试 - 重保持可靠性;大多数秤通过疾病严重程度表现出平均分数的显着差异。 ACRO-TSQ尺度与其他附带措施之间的相关性在绝对值中超过0.30,确认会聚有效性。 ACRO-TSQ比分评分的响应性反映了改善的疾病控制。估计MID症状干扰(10-12点),治疗方便(9-11)和GI干扰(8-10)。结论ACRO-TSQ是一个简要但全面的工具,用于监测与可注射的焦急性SSA治疗相关的重要成果。其内容反映了疾病和治疗负担以及患者满意度,以及其对临床研究的使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号